Ocrevus’s main immune cell target is B-cells, but a small study has shown that it can also lessen pro-inflammatory immune T-cells in patients with primary progressive multiple sclerosis.
Multiple Sclerosis (MS) is a chronic inflammatory, neurodegenerative, and demyelinating autoimmune disorder. The primary progressive form (PPMS) is characterized by a worsening of neurologic function with a gradual accumulation of disability from the onset of disease. The limited understanding of the pathogenesis of PPMS has hindered the development of reliable and effective treatments. However, there is an approved intravenous therapy, Ocrevus (ocrelizumab), a humanized monoclonal antibody developed by Genentech for treating patients with PPMS.